Evaluation of the effectiveness of TECAR therapy in carpal tunnel syndrome

Evaluation of the efficacy of TECAR © on the improvement of clinical and neuroelectrophysiological symptoms in patients with mild to moderate carpal tunnel syndrome.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220405054422N1

Enrollment

Registered

2022-04-30

Start date

2022-04-30

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal tunnel syndrome. Carpal tunnel syndrome

Interventions

Intervention 1: Intervention group: TECAR therapy for 15 minute in 8 session + wrist splint (one month) + vitamin B 1 300 mg daily. Intervention 2: Control group: TECAR therapy ( device off)for 15 m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with unilateral or bilateral idiopathic mild and moderate carpal tunnel syndrome confirmed by EMG-NCS and clinical test and lasting more than one month.

Exclusion criteria

Exclusion criteria: Systemic and local diseases (diabetes, RA, wrist arthritis, hypothyroidism, etc.) Cancer Pregnancy Burns on the hands and forearms IUD, Pacemaker, prosthesis Peripheral vascular diseases Fractures in the wrist and hand area Corticosteroid injection in the last trimester in the carpal tunnel

Design outcomes

Primary

Measure	Time frame
Symptom severity scale. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.;Functional status. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.;Pain. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Visual Analogue Scale.;Median SNAP peak latency. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median motor onset latency. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median SNAP amplitude. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median sensory NCV across wrist. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.	—

Measure

Time frame

Symptom severity scale. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.;Functional status. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.;Pain. Timepoint: At the beginning of the study and 1 and 2 months after treatment. Method of measurement: Visual Analogue Scale.;Median SNAP peak latency. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median motor onset latency. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median SNAP amplitude. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.;Median sensory NCV across wrist. Timepoint: At the beginning of the study and 2 months after treatment. Method of measurement: EMG machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid reza Ghasemi

Esfahan University of Medical Sciences

dr.ghasemi@resident.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026